Geoffrey Beene Cancer Research Center: Research Symposium

A Geoffrey Beene Cancer Research Symposium is held annually, featuring renowned global speakers. The symposium is open to Memorial Sloan Kettering Cancer Center's research community as well as members of the public.

2014

Autophagy and Cancer

Beth Levine, MD
Professor of Internal Medicine and Microbiology, University of Texas Southwestern Medical Center
Charles Cameron Sprague Distinguished Chair in Biomedical Science, Howard Hughes Medical Institute

David Sabatini, MD, PhD
Member, Whitehead Institute
Professor Biology, MIT
Investigator, Howard Hughes Medical Institute
Senior Associate Member, Broad Institute
Member, Koch Institute

Eileen White, PhD
Associate Director for Basic Science, Rutgers Cancer Institute of New Jersey
Distinguished Professor, Molecular Biology and Biochemistry
Rutgers, The State University of New Jersey

Monday, October 20, 2014
2:30 to 5:30 PM
Zuckerman Research Center Auditorium
417 East 68th Street
New York, NY 10065

“New Approaches to Targeted Therapy” - 2013

Martin Nowak, PhD
Harvard University
Evolutionary dynamics and treatment of cancer

Robert Schlegel, PhD
Novartis Institutes for Biomedical Research
Enhancing the impact of targeted therapy through drug combinations

Louis Staudt, MD, PhD
National Cancer Institute
Lymphoma therapy based on functional and structural genomics

“Cancer Heterogeneity” - 2012

The Regulation of Melanoma Metastasis
Sean Morrison, PhD
University Of Texas Southwestern Medical Center

Intratumor Heterogeneity: Challenges and Opportunities in Personalized Medicine
Charles Swanton, MD, PhD
London Research Institute

The Many Flavors of Resistance to Anti-Cancer Drugs
Jeffrey Settleman, PhD
Genentech, Inc.

View slide show of the 2012 Symposium

“Epigenome” - 2011

Epigenetic Clues to the Origins of Cancer
Peter W. Laird, PhD
University of Southern California

Chemical Inhibition of Bromodomains in Cancer
James E Bradner, MD
Dana-Farber Cancer Institute

Tissue-specific Interpretation by a Histone Reader
Michelle C. Barton, PhD
MD Anderson Cancer Center

View slide show of the 2011 Symposium

“Cancer Metabolism” - 2010

Oncogenic Reprogramming of Cell Metabolism and Therapeutic Opportunities
Chi Dang, MD, PhD
Johns Hopkins

IDH Mutations in Cancer
Valeria Fantin, PhD
Agios Pharmaceuticals

An Alternative Glycolytic Pathway in Proliferating Cells Promotes Anabolic Metabolism
Matthew Vander Heiden, MD, PhD
Massachusetts Institute of Technology

“Inflammation and Cancer” - 2009

Mechanisms Regulating Pro-Tumor Immunity During Cancer Development
Lisa Coussens, PhD
University of California San Francisco

Regulation of the Immune Response in Autoimmunity and Cancer
Richard Flavell, PhD, FRS
Yale University School of Medicine

The Role of Inflammation and Stem Cells in Gastric Cancer
Timothy Wang, MD
Columbia University

“Targeted Cancer Therapies” - 2008

PI3K and Cancer Metabolism
Lewis Cantley, PhD
Harvard Medical School

Clinical Development of Novel Anti Cancer Agents: Improvement Needed
Elizabeth Eisenhauer, MD
Queen's University

Therapeutics Targeting the PI3K/mTOR Pathway in Cancer
William Sellers, MD
Novartis Institutes of Biomedical Research

Chemical Genetic Approaches to Deciphering the PI3K/mTOR Pathway in Cancer
Kevan Shokat, PhD
University of California San Francisco

“Oncogenomics and Cancer Medicine” - 2007

Genetic and Genomic Approaches to Myeloid Malignancies
Gary Gilliland, MD, PhD
The Dana Farber Cancer Institute

Signatures for Cancer Discovery
Todd Golub, MD
The Broad Institute

Genomic Strategies for Personalized Cancer Therapy
Joseph Nevins, PhD
Duke University

Molecular Profiles Implemented in Clinical Decision Making
Laura van't Veer, PhD
The Netherlands Cancer Institute